CapsoVision, Inc CV
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
-30.12
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $13.6M | -$25.3M | $7.2M | -$23.0M | $13.3M |
| 2024 | $11.8M | -$19.9M | $6.4M | -$20.2M | -$129.5M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -30.12 (distress)
- Working capital / assets 0.674
- Retained earnings / assets -8.57
- EBIT / assets -1.405
- Equity / liabilities 2.704
Source: SEC EDGAR filings · CIK 0001378325 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.